Key facts
- It has raised $5.3M; the latest was Later Stage VC in Jan 2025.
- Notable investors include Plug and Play Tech Center, European Commission, Buenavista Equity Partners, Vedra Partners, Barca Innovation Hub — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Omniscope
- ·The full record, as it builds
Funding rounds
No funding rounds for Omniscope are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Omniscope
Developer of an AI-based platform designed to decode the immune system and enable cellular therapeutic development. The company's platform offers high-throughput immune sequencing and AI-powered analysis at an unprecedented scale through proprietary chemistry, enabling scientists and healthcare providers to enhance diagnostics and accelerate therapy development.
- Sector
- Healthcare
- HQ
- Dover, DE, United States
- Founded
- 2020
- Employees
- 37
- Website
- omniscope.ai/
- Ownership
- Privately Held (backing)
Omniscope doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Omniscope shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Omniscope in its N-PORT filings yet. We sweep new filings monthly.